De Novo device
Monarch eTNS System
Neurosigma, Inc. · Transcutaneous Nerve Stimulator For Adhd (QGL, Class II) · First FDA decision Apr 19, 2019, newest Apr 19, 2019ADHD
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
De Novo pathway
Device trials
4
Naming "Monarch eTNS"
MAUDE reports
0
Brand "Monarch eTNS", since 2015
PubMed studies
3
Mentioning "Monarch eTNS"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Monarch eTNS System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcutaneous Electrical Nerve Stimulators (TENS) - RETIREDNational determinationOn the books280.13Updated Jun 7, 2024
- Transcutaneous Electrical Nerve Stimulators (TENS)Local determinationIn effectL33802CGS Administrators, LLCUpdated Dec 7, 2023
- Transcutaneous Electrical Nerve Stimulation for Chronic Low Back PainNational analysisReview closedCAG-00429NUpdated Sep 24, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Low Back Pain (CLBP)National determinationOn the books160.27Updated Feb 10, 2026
- Transcutaneous Electrical Nerve Stimulation (TENS) for Acute Post-Operative PainNational determinationOn the books10.2Updated Dec 2, 2024
- Electrical Nerve StimulatorsNational determinationOn the books160.7Updated Aug 17, 2023
- Supplies Used in the Delivery of Transcutaneous Electrical Nerve Stimulation (TENS) and Neuromuscular Electrical Stimulation (NMES)National determinationOn the books160.13Updated Aug 16, 2023
- Phrenic Nerve StimulatorNational determinationOn the books160.19Updated Jun 12, 2020
Clinical trials
Device studies on ClinicalTrials.gov that name "Monarch eTNS", any status and sponsor, newest update first.
- Efficacy of Trigeminal Nerve Stimulation for ADHDPivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT05374187 · 218 participants · Start Sep 1, 2022 · Primary completion Apr 10, 2026
Device: Active eTNS; Sham eTNS · For: Attention-Deficit Hyperactivity Disorder
Sites: Los Angeles, California; Seattle, Washington
University of California, Los AngelesAcademic, hospital or other
NCT02155608 · 62 participants · Start Apr 1, 2015 · Primary completion May 30, 2018
Device: Active eTNS; Sham eTNS · For: Attention Deficit Hyperactivity Disorder (ADHD)
Sites: Los Angeles, California
University of California, Los AngelesAcademic, hospital or other
NCT03870737 · 22 participants · Start Dec 1, 2014 · Primary completion May 30, 2018
Device: Active TNS · For: Attention Deficit Hyperactivity Disorder (ADHD)
Sites: Los Angeles, California
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Monarch eTNS", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QGL
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Monarch eTNS"[tiab]. The summary above synthesizes these.
- Drugs for ADHD.
Med Lett Drugs Ther · 2020Review
- New frontiers in pharmacological treatment of attention-deficit hyperactivity disorder.
Noah AA, Sedky HE · Naunyn Schmiedebergs Arch Pharmacol · 2025Review, Research Support, Non-U.S. Gov't
- External trigeminal nerve stimulation versus sham stimulation for attention deficit hyperactivity disorder in children and adolescents aged 7-17 years: study protocol for a pilot and feasibility randomized clinical trial.
Edemann-Callesen H, Huus CL, Karstoft C, et al. · Eur Child Adolesc Psychiatry · 2025Clinical Trial Protocol
Other devices of this type
Also filed under product code QGL.
- Addnox (BPSPM1)Nu Eyne Co., Ltd. · 510(k) 2025
- BT-1000Bistos Co., Ltd. · 510(k) 2024
- Generation 2.0 Monarch external Trigeminal Nerve Stimulation (eTNS) System®Neurosigma, Inc. · 510(k) 2024
- SmileNu Eyne Co., Ltd. · 510(k) 2023
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.